Drugs

Vortioxetine

Pharmacogenomic Information
  

DrugTherapeutic Area*
Biomarker†
Referenced
Subgroup
Labeling Sections
VortioxetineNeurology
CYP2D6
CYP2D6 poor metabolizers
Dosage and Administration,
Clinical Pharmacology

 

* Therapeutic areas do not necessarily reflect the CDER review division.
 
 
† Standard nomenclature is used for genes as per the Human Genome Organization symbol, cytogenetic abnormalities as per the International System for Human Cytogenetic Nomenclature, or other conventions.

 

back to Table of Pharmacogenomic Biomarkers in Drug Labeling

Page Last Updated: 04/21/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.